CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. (NASDAQ:FMI) today announced that the discovery of a novel and potentially clinically actionable oncogenic gene fusion in lung cancer, NTRK1, using FoundationOne™, was published in the current online edition of Nature Medicine1. Lung cancer remains the leading cause of cancer-related death in men and women in the United States2; however, the use of targeted therapies in lung cancer has led to significant clinical benefit for patients with EGFR mutations and ALK fusions. Therefore, the identification of new, drug-sensitive oncogenes in this disease is of great clinical interest and has the potential to expand treatment options for patients.
Help employers find you! Check out all the jobs and post your resume.
